article thumbnail

The history – and the future – of antibody discovery technologies

DrugBaron

They can exploit their exquisite specificity to carry toxic payloads to specific locations, they can mimic the binding of natural ligands to act as agonists and they can even be engineered into bispecific (or multispecific) formats to hit several targets at once. The fourth milestone in antibody discovery is just beginning to unfold.

article thumbnail

Organoids: the versatile platform for discovery and regeneration

Drug Target Review

Engineered human pluripotent-stem-cell-derived intestinal tissues with a functional enteric nervous system. He received his BS in physics and biology from the University of Chicago and his PhD in molecular biology from the University of Pennsylvania. Schizophrenia risk from complex variation of complement component 4.

Treatment 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The Codon Guide to Synthetic Biology

addgene Blog

As I left the ivory tower and walked down into its foothills, I began to have conversations with many people who eagerly follow progress in synthetic biology, and want to be involved, but are overwhelmed by its vague and ill-defined contours.

article thumbnail

Cavro® ADP Detect: OEM design engineering drives molecular diagnostics automation

Tecan

By Mellisa Enriquez Cavro® ADP Detect: an overview Tecan's design engineering plays a crucial role in driving the automation of molecular diagnostics workflows. The Tecan Cavro ADP pipettor range has a proven track record of successful integration into molecular diagnostics platforms worldwide.

article thumbnail

Samuel DePalma

Broad Institute

in biomedical engineering from the University of Michigan under the guidance of Brendon Baker in the Engineered Microenvironments and Mechanobiology Lab. Prior to joining Bayer and the PCL, DePalma earned his Ph.D.

article thumbnail

Navigating the challenges of cell therapies

Drug Target Review

Ruella’s research indicated that the removal of CD5 from engineered T cell therapies resulted in increased cytotoxicity and improved anti-tumor efficacy in animal models. By harnessing the fundamental biology of T cells, Senza5 can be used to improve the efficacy of almost any CAR-T therapy.

Therapies 116
article thumbnail

Women in Stem with Dr Beate Mueller-Tiemann

Drug Target Review

I always found science fascinating, but I really fell in love with it in high school when I was introduced to biochemistry and molecular biology. Biochemistry and molecular biology fascinated me in school. Beate is an elected member of the Board of the Dechema, German Society for Chemical Engineering and Biotechnology.